Companies/US/PMN

PROMIS NEUROSCIENCES, INC.

Last · NasdaqCM$8.285-0.375 (-4.33%)close · yahoo · 15h ago
Vol 23.4K ≈ 194.0K
Market cap$74.30M9.0M sh
P/E · TTM-0.8fwd -1.8 · eps -11.65 · loss
Beta-0.25vs S&P 500
Div yield0.00%annual · TTM
52w range
$6.27$27.40
Volume23.4Ksession

Issuer

Legal namePROMIS NEUROSCIENCES, INC.
HQUnited States (US)
ListingUS PMN
ISINCA74346M5054
LEI5299007HZF79F9IAXI53
SectorHealthcare
IndustryDrugs (Pharmaceutical)
SIC2834
CurrencyUSD
Entity registrysec:0001374339
CIK0001374339
Websitewww.promisneurosciences.com
LinkedIn
Employees11
AddressProMIS Neurosciences, Inc. 1920 Yonge Street M4S 3E2, Toronto +416 847 6898
Loading chart…

Upcoming earnings

1 event
9:00 PM UTC+1
Period
Sep 2026
Est. EPS
−$1.82
Est. revenue
0
View upcoming earnings →

Earnings transcripts

2 recent

Press & signals

3 of 7 recent
  • GlobeNewswire

    ProMIS Neurosciences Appoints Seasoned Alzheimer’s and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer

  • GlobeNewswire

    ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September

  • GlobeNewswire

    ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights

The rest of this company's wire — with summaries and source links — is part of Pro.

See plans

Documents

FormReporting forFiledFlags
4
2026-10-052026-10-060
8-K8-K: Results of Operations and Financial Condition
2026-08-132026-08-130
10-Q
2026-06-302026-08-13 3
financial tablesPDF: ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate HighlightsIR
—2026-08-130
financial tablesPDF: ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate HighlightsIR
—2026-08-130
Showing 5 of 237 filings